<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3546138/" ref="ordinalpos=4855&amp;ncbi_uid=5651213&amp;link_uid=PMC3546138" image-link="/pmc/articles/PMC3546138/figure/F5/" class="imagepopup">Figure 5. Silencing of SC4MOL suppresses EGFR <span class="highlight" style="background-color:">signaling</span> and sensitizes A431 xenografts to cetuximab.  From: Targeting C4-demethylating genes in the cholesterol <span class="highlight" style="background-color:">pathway</span> sensitizes cancer cells to EGFR inhibitors via increased EGFR degradation. </a></div><br /><div class="p4l_captionBody">(A) Silencing SC4MOL in SCC61 cells suppresses phosphorylation of EGFR downstream effectors following EGF stimulation for indicated time intervals. (B) Effects of a single dose of cetuximab on A431 xenografts at 72 hours. Numbers below bands are tubulin-normalized densities relative to vehicle-treated shControl grafts. (C) Summary of results quantified from (B); *, p&lt;0.05. D Tumor volumes of xenografts of shRNA-modified A431 cells treated with cetuximab (closed symbols) or vehicle (open symbols); p-value (1) 2.2*10âˆ’16. (E) SCC61 cells depleted of SC4MOL are sensitized to erlotinib-induced suppression of AKT-mTOR pathway signaling. Graphs represent averaged results of 3 experiments; bars, SEM.</div></div>